Response to "Co-infections in COVID-19 critically ill and antibiotic management: a prospective cohort analysis"
Crit Care
.
2020 Sep 29;24(1):591.
doi: 10.1186/s13054-020-03308-4.
Authors
Marieke B Nieuwenhuis
1
,
Stefaan Van Biesen
2
,
Nicole P Juffermans
2
3
Affiliations
1
Department of Intensive Care Medicine, OLVG Hospital, Amsterdam, The Netherlands. M.Nieuwenhuis@olvg.nl.
2
Department of Intensive Care Medicine, OLVG Hospital, Amsterdam, The Netherlands.
3
Laboratory of Experimental Intensive Care and Anesthesiology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
PMID:
32993744
PMCID:
PMC7524375
DOI:
10.1186/s13054-020-03308-4
No abstract available
Publication types
Letter
Comment
MeSH terms
Anti-Bacterial Agents
Betacoronavirus
COVID-19
Cohort Studies
Coinfection*
Coronavirus Infections*
Critical Illness*
Humans
Pandemics*
Pneumonia, Viral*
Prospective Studies
SARS-CoV-2
Substances
Anti-Bacterial Agents